Non Hodgkin Lymphoma Clinical Trial

Study Evaluating CMC-544 In B-Cell Non-Hodgkin’s Lymphoma

Summary

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
At the expanded cohort, part 2 of the study, subjects must have one of the following:
Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
Diffuse large B-cell lymphoma
Age 18 years or older

Exclusion Criteria:

Candidate for potentially curative therapies in the opinion of the investigator
Chronic lymphocytic leukemia
Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

79

Study ID:

NCT00073749

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

UAB CCC Clinical Studies Unit
Birmingham Alabama, 35233, United States
University of Alabama at Birmingham Kirklin Clinic
Birmingham Alabama, 35233, United States
UAB Russell Ambulatory Pharmacy
Birmingham Alabama, 35294, United States
University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
Northwestern Medical Faculty Foundation
Chicago Illinois, 60611, United States
Northwestern Memorial Hospital
Chicago Illinois, 60611, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
The Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
M.D. Anderson Cancer Center
Houston Texas, 77030, United States
Universitair Ziekenhuis Gasthuisberg
Leuven , 3000, Belgium
Hopital Saint Louis
Paris , 75010, France
Centre Hospitalier Lyon-Sud
Pierre Benite Cedex , 69495, France
Universitätsklinikum Bonn
Bonn NRW, 53105, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet
Mainz , 55131, Germany
Medizinische Klinik und Poliklinik III, Klinikum der Universitat Muenchen-Grosshadern
Muenchen , 81377, Germany
Universitaet Muenchen Klinikum Grosshadern
Muenchen , 81377, Germany
Hospital de la Santa Creu I Sant Pau
Barcelona , 08025, Spain
Hospital Clinic I Provincial
Barcelona , 08036, Spain
Centre Hospitalier Universitaire Vaudois
Lausanne , 1011, Switzerland
St Bartholomew's Hospital
London , EC1A , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

79

Study ID:

NCT00073749

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider